Dr. Joseph Purvis is a Board Certified medical oncologist, with more than 35 years of pharmaceutical drug development experience in support of a wide range of molecules, including cytotoxics, hormonal agents, targeted small molecules and biologics. He has developed and conducted trials in all phases of global drug development, and has had significant experience working with regulatory authorities, particularly in North America and the EMEA. His regulatory experience includes oversight and preparation of documents for meetings and registration files, multiple meetings with regulatory authorities and advisors, as well as presentation at FDA Oncology Drug Advisory Committee (ODAC).

Dr. Purvis was an Attending Physician in the Hematology/Oncology Dept. at the Cleveland Clinic from 1981-86 after a fellowship at the Mayo Clinic. Next was Burroughs Wellcome where he led the development program for Navelbine®. He then joined Sanofi Pharmaceuticals, where he led the Team that licensed and developed Eloxatin®. Subsequently, he joined AstraZeneca, as the Development Lead for Breast and Prostate cancer, then led the US Oncology/Infection physician group. In 2008, he joined Wyeth as Assistant VP & Global Head for Oncology Medical Affairs. After the Pfizer acquisition in 2010, he joined Otsuka as VP & Global Head for Oncology Clinical Development, where he remained until June 2013. He joined Quintiles (now IQVIA) and was VP and Global Therapeutic Area Head for Oncology until June 2018. Since that time, he has provided independent expert consultation to a number of companies.

Dr. Purvis obtained his A.B. in Physics from Haverford College, and his M.D. from Jefferson Medical College. He completed his residency in Internal Medicine at Hartford Hospital, and fellowship in Medical Oncology at the Mayo Clinic.